Ind-Swift Laboratories Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/1vqu66dqj8vhi1u9qvilx921.pdf

Key Takeaways


Revenue Growth & Drivers

Aggarwal: "The guidance which we have given, we feel we are in a very comfortable position to achieve the projected numbers."

Margin Trajectory & Profitability

Aggarwal: "This is the minimum internal target which has been given to the entire team." (on crossing ₹1,000 crore top line with 20% EBITDA)

CDMO & Product Pipeline

Aggarwal: "As Ind-Swift the products which we are supplying in the regulated markets we’re not competing in that molecule with the innovator so that is a big difference because whatever CDMO we’re doing for our customers in Europe we’re not competing for that molecule with our partner."

Facilities & Capacity


Geographic & Customer Expansion

Aggarwal: "The focus of the management is very clear: to register more and more of our products in different countries where margins are good, giving us entire control of the product and the market."

Synthimed Labs & Balance Sheet

Aggarwal: "Since the valuations of the API business are growing, and they are in talks with two leading pharmaceutical companies based out of Hyderabad to acquire them as part of Synthimed, we feel this investment will grow. We should wait for a couple of years more before we liquidate our entire holding in this. But yes, some portion should be on the block in coming quarters."

Guidance & Commitments

CommitmentSpecificsTimeline
FY27 revenue growthMore than 50% YoY growthFY27 full year
FY27 blended EBITDA marginMore than 19%FY27 full year
Q3 FY27 EBITDA margin19% to 20%Q3 FY27
Internal minimum FY27 targetCross ₹1,000 crore top line with 20% EBITDAFY27
CDMO incremental revenue₹100–130 crore from CDMO partnershipsFY27
CDMO two-year incremental revenue₹200–220 crore from CDMO partnershipsFY27–FY28
Samba facility EU-GMP / PIC/S approvalApproval expected"Anytime next year"
ANVISA (Brazil) visit to SambaRegulatory inspectionProbably last quarter of FY27
Warehouse relocationShift from existing Derabassi facilityNext 10 to 12 months
R&D pipeline readiness11 molecules readyFY28–FY29
R&D pipeline readiness2 additional molecules readyFY29–FY30
Medium-term revenue CAGR20% to 25% CAGR to cross ₹1,500+ croreBy FY30
Medium-term margin expansion200 to 300 bps EBITDA margin expansionBy FY30
Q4 exit margin maintenanceMaintain 20%+ EBITDA level into next yearFY28
Export vs domestic mixAround 80% exports, 20% domesticGoing forward
CDMO vs own-brand mix~35% CDMO, ~65% own productsGoing forward

Key Metrics

MetricQ2 FY27
Operating Revenue₹234.89 cr, up 50.15% YoY and 26.22% QoQ
Operating EBITDA₹42.33 cr, up 4.95x YoY and 27.04% QoQ
Operating EBITDA Margin18.02%, expanded 1,256 bps YoY and 11 bps QoQ
PAT₹31.03 cr, up 3.54x YoY and 26.96% QoQ
PAT Margin13.21%, up 761 bps YoY
Raw Material Expenses45.15% of revenue, down from 49.38% a year ago
FY27 Revenue Growth GuidanceMore than 50% YoY, reiterated
Medium-term Revenue CAGR Guidance20% to 25% to cross ₹1,500+ cr by FY30
Medium-term EBITDA Margin Expansion Target200 to 300 bps expansion by FY30
Export Share of Total Sales82.7% of total sales
Own Brands Share of Sales55.75% of quarterly sales, 69% of export sales
Contract Manufacturing Share of Sales26.99% of quarterly sales
CDMO Export Revenue~₹65 cr in Q2 FY27
Own-Branding Export Revenue~₹125 cr in Q2 FY27
Atorvastatin + Ezetimibe Revenue~₹58 cr in Q2 FY27, up from ~₹25 cr in Q1 FY27
Ibuprofen Revenue (H1 FY27)~₹15 to ₹16 cr in H1 FY27
Global Product Registrations900+ across 85 countries, backed by 2,100+ filed dossiers
Additional Product Registrations Expected in FY27330+, with 100 to 150 already secured in H1 FY27
Samba Facility Capacity Utilization70% to 75%
Derabassi Facility Capacity Utilization70% to 75%
Net DebtCompletely net debt-free with robust cash and liquid reserves
Trade Receivables~₹234 cr, up from ₹168 cr; average realization cycle 75 days
R&D Expenses (Q2 FY27)~₹8 cr
Equity Stake in Synthimed Labs7.80%